'
Monsenso updates quality management system with new 2016 revision of ISO 13485 & annual audit of ISO 27001

Monsenso updates quality management system with new 2016 revision of ISO 13485 & annual audit of ISO 27001

ISO 13485 is an internationally agreed standard by ISO (the International Organization for Standardization) that sets out the requirements for a Quality Management System (QMS) specific to the medical devices industry. Monsenso mHealth solution first achieved DS/EN ISO 13485:2012 in July 11, 2016.

Developing our QMS is a continuous process. Recently, Monsenso has upgraded its QMS to the latest version of the standard EN ISO 13485 to the new revision: DS/EN ISO 13485:2016. Monsenso was audited by Bureau Veritas Certification Denmark A/S in June 2018 and found to be following the established procedures and the requirements of the standard DS/EN ISO 13485:2016.

So, what has Monsenso implemented in QMS to reflect the new standard and how does this affect users?

Quality management system with expanded risk management approach

According to the new version of the ISO standard, a risk based approach needs to be implemented in all the processes connected with the manufacturing of the medical device. This approach also include Monsenso’s suppliers.

In order to accommodate for this risk-based approach, Monsenso has implemented an extra layer of data security to our existing processes. This ensures that the evaluation / monitoring of our suppliers is proportionate to the risk associated with the purchased product. Monsenso’s critical suppliers are now placed on a risk level from I-IV, this ranking reflects the importance of the provided product relative to the medical device.

This implementation has helped to strengthen the control process of the suppliers, and helps to reduce risks that could potentially affect our customers and users of the product.

Closer to compliance with the requirements of the US market

Additionally, the new update of EN ISO 13845:2016 is in more alignment with US legislation and standards (FDA 21 CFR Part 820). Therefore, Monsenso is closer to meeting regulatory requirements of the FDA. FDA was a contributor to the new version and a lot of its regulation requirements are covered by this revision.

By upgrading their quality and security standards to become compliant with EN ISO 13845:2016, Monsenso has obtained an improved position to be aligned with worldwide requirements, including future compliance with FDA requirements on the US market.

Annual audit of ISO 27001 Information Security Management System

At the same time, Monsenso went through annual audition of ISO 27001. Compliance with this certification validates that Monsenso’s comprehensive information security practices protect its users and their information in accordance with internationally recognised standards.

The ISO 27001 standard ensures the secure management of customers’ information, intellectual property, and third party information by establishing methodologies and meeting key objectives for implementing information security.


MHealth solution enables information-sharing among patients, carers and clinicians

MHealth solution enables information-sharing among patients, carers and clinicians

Copenhagen, Denmark – 15 March 2016.  Monsenso ApS, an innovation leader in mobile health (mHealth) solutions for mental health, announced today the development of a triple-loop mHealth solution that enables information-sharing between patients, carers and clinicians to support the treatment of 1,000 individuals suffering from schizophrenia.

The mHealth solution, designed and developed by Monsenso, will provide healthcare professionals and family caregivers with access to the patient’s information.

Patients will be encouraged by their care providers to download the Monsenso smartphone app that will allow them to invite their care providers and family caregivers to access their data.

The smartphone app will be used to fill in routine self-assessments that reveal their current state of mind, and to collect sensor data.  It can also be used as a self-management tool that allows patients to manage their symptoms and the behaviours that trigger those symptoms.

Once invited by the patient, a family caregiver will be able to use a similar app to access the patient’s aggregated data and fill in the routine assessments evaluating the patient’s state of mind.

Healthcare professionals will use a web portal where they can access all the data collected by the patients’ and caregivers’ smartphones anytime, anywhere. The web portal enables clinicians to view relevant information related to each patient.

In relation to the development of the triple-loop solution, Thomas Lethenborg, CEO at Monsenso, commented. “We are approaching treatment in a way that has never been done before. There are currently a few mHealth solutions that offer a double-loop treatment model for patients and care providers. However, Monsenso will be the first company ever to develop and implement an mHealth platform that involves patients, care providers and family caregivers in the treatment of a mental illness. The caregiver module, which is currently under development, will be ready to be rolled out in Q3 2016, and will initially be used for two years.”

For additional information contact:

Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

You can download this article as PDF in English and Danish